Italia markets open in 4 hours 54 minutes

Syros Pharmaceuticals, Inc. (0LC7.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a portafoglio
2,0382-0,0598 (-2,85%)
Alla chiusura: 02:42PM GMT

Syros Pharmaceuticals, Inc.

35 CambridgePark Drive
4th Floor
Cambridge, MA 02140
United States
617 744 1340
https://www.syros.com

Settore/i
Settore
Impiegati a tempo pieno103

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Dr. Nancy A. Simonian M.D.Pres, CEO & Director1,03MN/D1961
Dr. Richard A. Young Ph.D.Scientific Founder, Member of Scientific Advisory Board & Director165kN/D1954
Dr. Eric R. OlsonChief Scientific Officer696,42kN/D1958
Dr. David A. RothChief Medical Officer713,03kN/D1963
Dr. James E. Bradner M.D.FounderN/DN/D1972
Dr. Nathanael S. Gray Ph.D.Scientific Founder & Member of Scientific Advisory BoardN/DN/DN/D
Mr. Jason HaasChief Financial OfficerN/DN/DN/D
Mr. Gerald E. QuirkChief Operations Officer & Sec.N/DN/D1968
Ms. Naomi AokiVP of Corp. Communications & Investor RelationsN/DN/DN/D
Dr. Christian C. Fritz Ph.D.Head of BiologyN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2020 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are SY-1425, a selective retinoic acid receptor alpha agonist, which is in Phase II clinical trial for genomically defined subset of patients with acute myeloid leukemia and phase III clinical trial for patents with myelodysplastic syndrome; SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors; and SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Syros Pharmaceuticals, Inc. al 26 settembre 2021 è 7. I criteri di valutazione fondamentali sono revisione: 6; Consiglio di Amministrazione: 6; diritti degli azionisti: 8; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.